Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib

Charles Chuah¹
Junia V Melo²

¹Singapore General Hospital and Duke-NUS Graduate Medical School, Singapore; ²Institute of Medical and Veterinary Science, South Australia, Australia

Abstract: The efficacy of imatinib in chronic myeloid leukemia has been remarkable, but the development of resistance and the persistence of minimal residual disease have dampened the initial enthusiasm for this much heralded ‘magic bullet’. Much progress has been made in elucidating the mechanisms which underlie imatinib resistance. The most common cause of such drug resistance is the selection of leukemic clones with point mutations in the Abl kinase domain leading to amino acid substitutions which prevent the appropriate binding of the drug. Other mechanisms include genomic amplification of BCR-ABL and modulation of drug efflux or influx transporters. Dasatinib is a multi-target kinase inhibitor which has increased potency and is able to inhibit most Bcr-Abl mutant cell lines. Clinical trials of dasatinib in imatinib-resistant and -intolerant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoid leukemia have shown that it is effective and well tolerated. In this review, we will discuss the pre-clinical development of dasatinib, the clinical trial data demonstrating its efficacy and tolerability and highlight certain aspects of its toxicity profile and mechanisms of resistance.

Keywords: drug resistance, tyrosine kinase inhibitors, Bcr-Abl

Introduction

Imatinib has, without doubt, been a major achievement for the treatment of chronic myeloid leukemia (CML), but resistance to this drug has become and will continue to be a therapeutic challenge. In early chronic phase (CP-CML) patients treated with imatinib at diagnosis, 18% failed to achieve a complete cytogenetic response (CCyR) after a median follow-up of five years while 6% progressed to the advance phase and 8% had a cytogenetic or hematologic relapse.¹ Among CP-CML patients who had failed prior interferon treatment, 43% did not achieve a CCyR after a median duration of imatinib treatment of 65 months and 39% progressed to the advance phase.² Not surprisingly, in advanced phase patients treated with imatinib, resistance or relapse occurred in 75% of accelerated phase (AP-CML) and 95% of myeloid blast crisis (MBC-CML) patients.³ Single agent therapy with imatinib may not be the best long-term option in CML, at least for a proportion of patients, and other strategies need to be explored. Many novel compounds are currently being investigated pre-clinically and clinically, and therapeutic approaches to circumvent the problem of imatinib-resistance are now possible. Dasatinib (BMS-354825, Sprycel; Bristol-Myers Squibb, New York, NY) and other Bcr-Abl tyrosine kinase inhibitors (TKI), such as nilotinib (AMN107, Tasigna; Novartis, Basel, Switzerland) and bosutinib (SKI-606; Wyeth, Madison, NJ) represent the newer generation of TKIs which have been shown to be effective and safe in imatinib-resistant and -intolerant CML patients.
Pre-clinical development of dasatinib

The disruption of the proto-oncogene Src is associated with the pathogenesis of human cancers. Several synthetic small molecule inhibitors of Src-family kinases (SFK) have been developed, such as PD180970, AP23464, CGP76030, dasatinib, and bosutinib. These compounds also inhibit Bcr-Abl, Kit and platelet-derived growth factor receptor β (PDGFRβ), and have in vitro antiproliferative activity in imatinib-sensitive and -resistant CML cells.

Dasatinib was identified among a series of novel 2-(aminopyridyl)-and 2-(aminopyrimidinyl)-thiazole-5-carboxamides as a compound with broad spectrum antiproliferative activity against hematological and solid tumor cell lines, and favorable pharmacokinetics after oral dosing. X-ray crystallographic studies of the three-dimensional structure of Abl kinase complexed with dasatinib revealed that the compound binds to the activation loop of Abl in an active conformation. In addition, interactions between the Abl ATP-binding site and dasatinib were less critical for binding, suggesting that the compound would be active against the mutant kinase forms. Initial studies revealed that dasatinib is a potent multi-target kinase inhibitor of Bcr-Abl, SFK (Src, Lck, and Yes), PDGFRβ and Kit at nanomolar to sub-nanomolar concentrations (Table 1).

Recently, dasatinib was also shown to bind to other tyrosine and serine/threonine kinases, such as the TEC family kinases, BTK and TEC, the mitogen-activated protein kinases, the receptor tyrosine kinase, discoidin domain receptor 1 and the ephrin receptors.

Biochemical assays using purified GST-Abl kinase and cellular proliferation and Bcr-Abl tyrosine phosphorylation assays revealed that dasatinib was approximately 325 times more potent than imatinib. Dasatinib was also able to inhibit the cellular proliferation, peptide substrate and Bcr-Abl tyrosine phosphorylation of all Bcr-Abl mutants at nanomolar concentrations with the exception of the T315I mutant. In addition, in vivo studies in murine models demonstrated the activity of dasatinib in inhibiting the leukemic cell growth and prolonging the survival of mice harboring wild type Bcr-Abl and the M351T, but not the T315I mutant.

Clinical efficacy of dasatinib

Based on the promising pre-clinical data, clinical trials were embarked upon to test the efficacy and safety of dasatinib in patients who were resistant to or intolerant of imatinib.

Phase I study

CA180002 was a dose-escalation study for patients with imatinib-resistant or -intolerant CML or Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). A total of 84 patients were enrolled into the study. Dasatinib was administered at total daily doses ranging from 15 to 240 mg, once or twice daily. Dasatinib was generally well tolerated. Grade 3 or 4 hematologic suppression was common especially in the advanced phases, resulting in treatment interruption in 60% and dose reduction in 25% of patients. Nonhematologic toxicities included pleural effusion, diarrhea, nausea, vomiting, gastrointestinal hemorrhage, peripheral or periorbital edema, pericardial effusion, pulmonary edema, rash, flushing, headache, fatigue, and tumor lysis syndrome. Most of these toxicities were grade 1 or 2 and the maximum tolerated dose (MTD) was not determined. Cross-intolerance with imatinib was not evident.

Complete hematologic responses (CHR) were achieved in 92% of CP-CML, 45% of AP-CML, 35% of MBC-CML and 70% of lymphoid blast crisis (LBC-CML) or Ph+ ALL patients. Major cytogenetic remission (MCyR) were also observed in 45% of CP-CML, 27% of AP-CML, 35% of MBC-CML, and 80% of LBC-CML or Ph+ ALL patients. Most of these responses occurred in patients receiving doses of 50 to 70 mg twice a day. Responses were seen in patients harboring the Bcr-Abl kinase mutations other than the T315I mutant.

Phase II studies

As the MTD of dasatinib was not defined in the phase I study, the phase II dose was based on its efficacy, and all patients, regardless of phase of disease, received 70 mg twice daily. The START (Src/Abl Tyrosine kinase inhibition Activity: Research Trials of dasatinib) clinical trials comprised

Table I Kinase profile of dasatinib

<table>
<thead>
<tr>
<th>Kinase</th>
<th>Enzyme IC&lt;sub&gt;50&lt;/sub&gt;, nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bcr-Abl</td>
<td>1.0</td>
</tr>
<tr>
<td>Src</td>
<td>0.5</td>
</tr>
<tr>
<td>Lck</td>
<td>0.4</td>
</tr>
<tr>
<td>Yes</td>
<td>0.4</td>
</tr>
<tr>
<td>C-kit</td>
<td>5</td>
</tr>
<tr>
<td>PDGFRβ</td>
<td>28</td>
</tr>
<tr>
<td>p38</td>
<td>100</td>
</tr>
<tr>
<td>Her1</td>
<td>180</td>
</tr>
<tr>
<td>Her2</td>
<td>710</td>
</tr>
<tr>
<td>FGFR-1</td>
<td>880</td>
</tr>
<tr>
<td>MEK</td>
<td>1700</td>
</tr>
</tbody>
</table>
Dasatinib for imatinib-resistance

There were similar hematologic and cytogenetic responses in dasatinib phase II trials.

### Table 2: Hematologic and cytogenetic responses in dasatinib phase II trials

<table>
<thead>
<tr>
<th>Stage of disease</th>
<th>Median duration of treatment (months)</th>
<th>CHR (%)</th>
<th>MCyR (%)</th>
<th>CCyR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-CML (n = 387)</td>
<td>13.8</td>
<td>91</td>
<td>59</td>
<td>49</td>
</tr>
<tr>
<td>AP-CML (n = 107)</td>
<td>8.3</td>
<td>39</td>
<td>33</td>
<td>24</td>
</tr>
<tr>
<td>MBC-CML (n = 109)</td>
<td>3.5</td>
<td>27</td>
<td>33</td>
<td>26</td>
</tr>
<tr>
<td>LBC-CML (n = 48)</td>
<td>2.9</td>
<td>29</td>
<td>52</td>
<td>46</td>
</tr>
</tbody>
</table>

**Abbreviations:** CHr, complete hematological response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; CP-CML, chronic phase; AP-CML, accelerated phase; MBC-CML, myeloid blast crisis; LBC-CML, lymphoid blast crisis.
twice daily regimen with a total daily dose of 100 mg or 140 mg in CP-CML patients who were resistant or intolerant to imatinib.

Six hundred and seventy CP-CML patients were randomized between four dasatinib treatment arms: 100 mg once daily, 50 mg twice daily, 140 mg once daily, or 70 mg twice daily. With a minimum follow-up of 24 months and median treatment duration of 22 months, the CHR rates (87% to 92%) and CCyR rates (61% to 63%) were comparable in all four groups. Among the patients who achieved a CCyR, the median time to CCyR with dasatinib 100 mg once daily was 13.0 weeks, compared with 12.9 to 13.8 weeks for the other treatment arms. The major molecular response (MMR) rate was 38% in the four cohorts. The PFS and OS in the 100 mg once daily group at 24 months was 80% and 91%, respectively. Again, these were comparable to the other arms. The incidence of pleural effusion of any grade in the 100 mg once daily treated patients was less than in the other patients (14% versus 23%–25%, p = 0.049). Grade 3 or 4 thrombocytopenia was also less frequent in the 100 mg once daily arm (23% versus 36%–41%, p = 0.003). There was a trend towards a lower incidence of grade 3 or 4 neutropenia in the 100 mg once daily cohort but this was not statistically significant (35% versus 44%–47%, p = 0.127). Treatment with dasatinib 100 mg once daily was also associated with the lowest incidence of treatment interruption (62% versus 72%–79%), dose reduction (39% versus 46%–62%) and discontinuation due to drug toxicity (12% versus 16%–21%). These findings confirm that the current approved dose of dasatinib 100 mg once daily in CP-CML offers the most favorable long-term benefit-risk assessment. In addition, these observations are further supported by a recent study which shows that transient in vitro inhibition of Bcr-Abl, through high-dose dasatinib pulse therapy, is sufficient to induce irreversible cytotoxicity in CML cells.

The once or twice daily schedule with a total daily dose of 140 mg was also investigated in advanced phase patients. A total of 317 AP-CML patients was assigned randomly to either 140 mg once daily or 70 mg twice daily. After a minimum follow-up of 24 months, the CHR rates (47% versus 52%) and MCyR rates (39% versus 43%) were similar in the once daily and twice daily arms. The median PFS was comparable in the two groups. Patients in the once-daily arm had significantly fewer pleural effusions of any grade compared to those in the twice daily arm (20% versus 39%, p < 0.001). The rates of the other nonhematologic and hematologic toxicities were similar between both arms.

There was no appreciable difference in efficacy or treatment-related toxicities in the blast crisis-CML (BC-CML) patients who were treated with 140 mg once daily or 70 mg twice daily. However, there was a suggestion that the once daily dose may improve tolerability as evidenced by a lower incidence of dose reduction (4%–6% versus 10%–11%).

### Table 3: Hematologic and cytogenetic responses in nilotinib phase II trials

<table>
<thead>
<tr>
<th>Stage of disease</th>
<th>Median duration of treatment (months)</th>
<th>CHR (%)</th>
<th>MCyR (%)</th>
<th>CCyR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-CML (n = 321)</td>
<td>19</td>
<td>94</td>
<td>59</td>
<td>44</td>
</tr>
<tr>
<td>AP-CML (n = 138)</td>
<td>8.9</td>
<td>31</td>
<td>32</td>
<td>20</td>
</tr>
<tr>
<td>BC-CML (n = 136)</td>
<td>NR</td>
<td>11</td>
<td>40</td>
<td>29</td>
</tr>
</tbody>
</table>

**Abbreviation:** AP-CML, accelerated phase; BC-CML, blast crisis; CP-CML, chronic phase; CHR, complete hematological response; CCyR, complete cytogenetic response; MCyR, major cytogenetic response; NR, not reported.

### Table 4: Hematologic and cytogenetic responses in bosutinib phase II trials

<table>
<thead>
<tr>
<th>Stage of disease</th>
<th>Median duration of treatment (months)</th>
<th>CHR (%)</th>
<th>MCyR (%)</th>
<th>CCyR (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-CML (102 evaluable)</td>
<td>7.3</td>
<td>81</td>
<td>47</td>
<td>34</td>
</tr>
<tr>
<td>AP-CML (30 evaluable)</td>
<td>5.5</td>
<td>54</td>
<td>47</td>
<td>27</td>
</tr>
<tr>
<td>BC-CML (17 evaluable)</td>
<td>2.5</td>
<td>36</td>
<td>53</td>
<td>35</td>
</tr>
</tbody>
</table>

**Abbreviations:** AP-CML, accelerated phase; BC-CML, blast crisis; CCyR, complete cytogenetic response; CP-CML, chronic phase; CHR, complete hematological response; MCyR, major cytogenetic response.
Predictors of response to dasatinib

The knowledge that the Bcr-Abl kinase mutations have varying degrees of *in vitro* sensitivity to dasatinib may allow its use in a rational manner. For example, the highly resistant T315I mutant would be expected to confer refractoriness to dasatinib in patients harboring this mutant. It is also conceivable that patients with mutant clones which have intermediate *in vitro* resistance may not have an optimal response to dasatinib. In an analysis of 1,043 CP-CML patients enrolled into the phase II and III dasatinib trials, 402 patients had one or more baseline Bcr-Abl kinase mutations. The T315I mutant was detected in 21 patients and not surprisingly, the majority did not achieve any response with dasatinib. Excluding the T315I mutant, 44 patients had a mutation with a known dasatinib cellular IC₅₀ of more than 3 nM (Q252H, E255K/V, V299L and F317L). Although responses to dasatinib were observed in patients who had any of these five mutations, the frequency of responses was less compared to that of patients who had mutations with a dasatinib cellular IC₅₀ of less than 3 nM or with unknown IC₅₀ (Table 5).

Apart from using existing Bcr-Abl kinase mutations to predict response to dasatinib and other second generation TKI, it may be possible to predict the probability of achieving CCyR using baseline clinical features. A multivariate analysis of 80 imatinib-resistant or -intolerant patients, who were treated with dasatinib (n = 67) or nilotinib (n = 13) revealed that a low Sokal risk score at diagnosis, the best cytogenetic response on imatinib, the use of growth factor support during imatinib treatment and the time from detection of imatinib failure to commencement of a second generation TKI were predictive factors for achieving CCyR.

Early responses may also be predictive of subsequent responses. In a study of 113 patients (87 CP-CML, 26 AP-CML) who were treated with either dasatinib (n = 70) or nilotinib (n = 43), patients who achieved a minor cytogenetic response at three or six months, compared to those who did not, had a significantly higher probability of achieving a MCyR at 12 months. The molecular response after three months of a second generation TKI was also highly predictive of attaining a MMR. An analysis of 155 CP-CML patients treated with dasatinib (n = 82) or nilotinib (n = 73) showed that attaining a BCR-ABL transcript level of less than or equal to 1% by the International Scale at three months resulted in an 86% probability of achieving a MMR at 24 months. This was significantly higher than the probability for those who had a level between 1% and 10% (55% probability, p = 0.0003) and those with levels more than 10% (4% probability, p < 0.0001). In the group with BCR-ABL transcript levels of more than 10% by the international scale, those with a level of 50% or more had a significantly lower probability of attaining a MCyR at 24 months, compared to those with levels between 10% and 50% (11% versus 56%, p = 0.003).

Therefore, pre-existing Bcr-Abl kinase mutations, certain pre-treatment disease features and early cytogenetic and molecular responses are useful in predicting the subsequent clinical responses in patients on dasatinib therapy.

**Significance of dasatinib-induced response in CP-CML**

In the first-line treatment of CML with imatinib, the achievement of a MCyR at 12 months and a MMR at 18 months is associated with a significantly lower probability of disease progression at five years. An analysis of 448 imatinib-resistant or -intolerant CP-CML patients showed that after 12 months of treatment with dasatinib, 57% achieved a MCyR and 45% a CCyR. Achievement of a MCyR at 12 months was associated with a higher 24-month PFS of 94%, compared to 79% in those who did not (p < 0.0001). Likewise, patients who achieved a CCyR at 12 months had a higher 24-month PFS than those who did not (95% versus 82%, p = 0.0003). In a separate evaluation of 1,150 CP-CML patients, 35% achieved a MMR within a median time of 5.7 months. A landmark analysis showed that achieving a MMR at 12 months conferred a 24-month PFS of 96% which was significantly higher than not attaining that milestone (82%, p < 0.0001). These preliminary data suggest that the attainment of a MCyR, CCyR, or MMR at 12 months in dasatinib-treated CP-CML patients may lead to a higher PFS.

**Dasatinib in the treatment of Ph+ central nervous system leukemia**

The penetration of imatinib into the cerebrospinal fluid (CSF) is poor, leading to insufficient concentrations for kinase...
inhibition. Not surprisingly, central nervous system (CNS) leukemic relapses are common in imatinib-treated patients with LBC-CML, MBC-CML, or Ph+ ALL in spite of complete responses in the peripheral blood and bone marrow. A case report of a dasatinib-induced clinical response in Ph+ CNS leukemia led to the further investigation of its utility for these cases. Using a mouse model, where a human CML tumor cell line was implanted intracranially, treatment with dasatinib significantly increased the median survival time compared to the control and the imatinib-treated groups. The antitumor activity, as assessed by bioluminescence imaging, was also decreased in the dasatinib-treated group. However, when dasatinib was stopped, the intracranial tumors recurred and all the mice died. Pharmacokinetic analysis also showed that although dasatinib brain concentrations were 12 to 31 times lower than that in the plasma, the levels were adequate to inhibit 50% of cellular proliferation of the CML cell line in vitro.

A study of 11 patients with Ph+ CNS leukemia treated with dasatinib revealed that all the patients had a clinical response. Complete responses were achieved in seven patients, of which four were treated with dasatinib alone. These responses were durable, lasting between three to 12 months. Interestingly, dasatinib-resistant Bcr-Abl kinase mutants (T315I and V299L) were detected in the CSF leukemic blasts of two patients who developed a CNS relapse on dasatinib, suggesting that the selection of a resistant clone, rather than poor CSF penetration, was the cause of relapse.

**Dasatinib in children and adolescents**

The role of dasatinib in children and adolescents was investigated in a phase I/II dose-finding study which enrolled 25 patients with CP-CML, advanced phase CML or Ph+ acute leukemia, as well as 22 patients with Ph-negative acute leukemia. The median age was 10 years and all patients were heavily pre-treated. Dasatinib was well tolerated up to 120 mg/m² once daily, and the MTD was not reached. CML or Ph+ acute leukemia patients were given a dose of 60 or 80 mg/m² once daily. Common treatment-related adverse events included nausea, vomiting, diarrhea, headache and rash. Among the 12 CP-CML patients, 83% achieved a CHR and 67% a MCyR after a median duration of treatment of 58 days. A CHR rate of 23% and CCyR rate of 62% was obtained in the 13 advanced phase or Ph+ acute leukemia patients. The preliminary findings indicate that dasatinib is effective and tolerable in children and adolescents with Ph+ leukemia.

**Dasatinib-related toxicities**

Dasatinib is generally well tolerated and its toxicity profile is similar, but not identical, to that of the other TKIs (Tables 6 and 7). However the incidence of cytopenias, pleural effusion and immune-mediated adverse events in patients treated with dasatinib are higher than those on imatinib or nilotinib therapy. This could be due, in part, to dasatinib’s higher potency and wider spectrum of kinase inhibition. The fact that there is some differential toxicity between the three drugs may be actually important and useful for a decision on which inhibitor to use or to change to in case of resistance to one of them.

**Myelosuppression**

Regardless of the phase of disease, grade 3 or 4 neutropenia and thrombocytopenia occurs more commonly in patients treated with dasatinib than those on imatinib, nilotinib or bosutinib (Table 6). This is probably a reflection of its more potent inhibition of Bcr-Abl and Kit. Myelosuppression is generally manageable with dose interruption and reduction. The incidence of grade 3 or 4 cytopenia was also reduced in CP-CML patients who were treated with the 100 mg once

<table>
<thead>
<tr>
<th>Table 6 Incidence of grade 3 or 4 cytopenias in phase II studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>CP-CML (%)</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td><strong>Imatinib 400 or 600 mg</strong></td>
</tr>
<tr>
<td>Neutropenia</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td><strong>Nilotinib 400 mg</strong></td>
</tr>
<tr>
<td>Neutropenia</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td><strong>Bosutinib 500 mg</strong></td>
</tr>
<tr>
<td>Neutropenia</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
</tr>
<tr>
<td><strong>Dasatinib 70 mg</strong></td>
</tr>
<tr>
<td>Neutropenia</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
</tr>
</tbody>
</table>

**Abbreviations:** AP-CML, accelerated phase; CP-CML, chronic phase; MBC-CML, myeloid blast crisis.
Dasatinib for imatinib-resistance

Pleural effusion
Dasatinib-related pleural effusion is a frequent adverse event occurring in 7%–35% of patients, with the lowest frequency in CP-CML patients receiving the 100 mg once daily dose and the highest in MBC-CML patients receiving the 70 mg twice daily dose. The median time from the start of dasatinib to the development of pleural effusion was 84 days in MBC-CML patients and 315 days in CP-CML patients taking dasatinib 100 mg once daily. Pleural fluid analysis revealed that the majority of cases were exudative in nature with a predominance of lymphocytes. The management of pleural effusion includes dose interruption and reduction, diuretics, corticosteroids and, in severe cases, thoracentesis. Two separate multivariate analyses identified that certain clinical features were associated with an increased risk of developing pleural effusion. In one study, prior cardiac history, hypertension and a twice-daily dasatinib schedule were independent predictors for the development of pleural effusion. In the second study, the associated factors were hypercholesterolemia, a history of skin rash on imatinib and a previous history of autoimmune disease. The latter association and the observations that dasatinib-related pleural effusion has a lymphocyte predominance and is responsive to corticosteroids suggest that the pathogenesis of pleural effusion may be immune-mediated. The inhibition of PDGFRβ by dasatinib has also been implicated as a cause of pleural effusion, and it has been shown that PDGFRβ-deficient mouse embryos develop defective blood vessels and edema due to a loss of microvascular pericytes.

Dasatinib-induced immune-mediated complications
Dasatinib is a potent inhibitor of the SFK member, Lck, which is involved in T-cell receptor (TCR) signaling and activation. It has been shown to suppress TCR-mediated signaling, cellular proliferation, cytokine production, in vivo T-cell responses and in vitro natural killer cell cytotoxicity. These findings suggest that patients taking dasatinib may be prone to opportunistic infections due to potential T-cell inhibition, and that dasatinib may, in fact, have a therapeutic role for T-cell mediated immune disorders such as graft-versus-host disease or rheumatoid arthritis. However, dasatinib-induced Lck inhibition has also been implicated in the pathogenesis of autoimmune disorders in two recent case reports. In the first case, the patient presented with respiratory symptoms, diffuse ground glass opacities on thoracic high-resolution computer tomography and appearance of antinuclear and anti-DNA antibodies after 29 days of treatment with dasatinib. The second case developed fever, arthralgia, pleural effusion, pericardial effusion and autoantibodies after 6 months of dasatinib therapy, suggesting a possibility of dasatinib-induced lupus. In both cases, the autoantibodies were not present before dasatinib. After cessation of dasatinib, the symptoms were resolved and the autoantibody levels were decreased in the former case and were undetectable in the latter.

Another possible mechanism underlying the immune-mediated toxicities is the clonal expansion of natural killer/T-cell lineage large granular lymphocytes (LGL). LGL lymphocytosis has been observed in patients on dasatinib and this correlated with the achievement of complete molecular responses. However, patients with LGL lymphocytosis had a high incidence of dasatinib-related adverse events with
more than 50% developing pleural effusion, pneumonitis, CMV reactivation, colitis and prolonged fever.57

Mechanisms of resistance to dasatinib

Three major mechanisms have been identified for imatinib resistance. The two most common affect the BCR-ABL gene itself, namely mutations in its tyrosine kinase domain and overexpression of the Bcr-Abl protein due to amplification of the BCR-ABL gene.58-62 The third mechanism is represented by phenomena which lead to Bcr-Abl-independent resistance. These include upregulation of the ABCB1 or ABCG2 drug efflux pumps,58,63,64 downregulation of human organic cation transporter 1 (hOCT1) drug influx transporters,65,66 overexpression of Lyn, a Src-family kinase,67 and other Bcr-Abl-independent mechanisms. Dasatinib, due to its increased potency and efficacy against most of the imatinib-resistant Bcr-Abl kinase mutations, has been able to overcome most forms of imatinib resistance mediated by the former two mechanisms. However, resistance to dasatinib has also become an emerging therapeutic problem.

Dasatinib-resistant Bcr-Abl kinase mutations

Pre-clinical in vitro and in vivo studies have shown that the T315I mutant is resistant to dasatinib.9,11 The dasatinib cellular IC50 for this mutant is more than 250 times higher than that for wild type Bcr-Abl, and kinase activity is not inhibited even in the presence of micromolar concentrations of the drug.9,13 Dasatinib treatment did not reduce leukemic burden nor improve survival of mice harboring the T315I mutant.16 Co-crystal studies have demonstrated that the T315 is a critical contact residue for dasatinib.69 Dasatinib interacts with the side chain of T315 by a hydrogen bond and loss of this hydrogen bond in the T315I mutant, together with an increased steric bulk in this pocket, are the most likely causes of dasatinib resistance.69 Not surprisingly, nearly all imatinib-resistant patients with the T315I mutant did not have any clinical response to dasatinib.15-17,31,70

Using two different in vitro mutagenesis screening techniques, twelve Bcr-Abl mutants at six sites were identified which conferred in vitro resistance to dasatinib (Table 8).71,72 Crystallographic studies have shown that four of these six sites (L248, V299, T315, and F317) are dasatinib contact residues.69 Dasatinib makes contact with L248 and G321 by van der Waals interactions and the 2-chlor-6-methyl phenyl ring of dasatinib occupies a hydrophobic pocket composed of

<table>
<thead>
<tr>
<th>Predicted mutation</th>
<th>Bradeen et al17</th>
<th>Burgess et al72</th>
</tr>
</thead>
<tbody>
<tr>
<td>L248R</td>
<td></td>
<td>+ (12)</td>
</tr>
<tr>
<td>L248V</td>
<td>+ (2)</td>
<td></td>
</tr>
<tr>
<td>Q252H</td>
<td>+ (2)</td>
<td>+ (NR)</td>
</tr>
<tr>
<td>E255K</td>
<td>+ (7)</td>
<td>+ (9.7)</td>
</tr>
<tr>
<td>V299L</td>
<td>+ (13.4)</td>
<td>+ (13.4)</td>
</tr>
<tr>
<td>T315A</td>
<td></td>
<td>+ (93)</td>
</tr>
<tr>
<td>T315I</td>
<td>+ (&gt;750)</td>
<td>+ (&gt;750)</td>
</tr>
<tr>
<td>T315I</td>
<td>+ (&gt;750)</td>
<td>+ (&gt;750)</td>
</tr>
<tr>
<td>F317C</td>
<td>+ (NR)</td>
<td>+ (NR)</td>
</tr>
<tr>
<td>F317I</td>
<td>+ (NR)</td>
<td>+ (NR)</td>
</tr>
<tr>
<td>F317L</td>
<td>+ (9)</td>
<td>+ (13.4)</td>
</tr>
<tr>
<td>F317S</td>
<td></td>
<td>+ (NR)</td>
</tr>
<tr>
<td>F317V</td>
<td>+ (40)</td>
<td>+ (40)</td>
</tr>
</tbody>
</table>

Notes: (1) = fold dasatinib IC50 wild type Bcr-Abl.

T315, M290, V299, I313, and A380.69 The aromatic ring in the side chain of F317 interacts directly with the pyrimidine and thiazole rings of dasatinib.69

Consistent with the in vitro mutagenesis data, the selection of the V299L, T315I, and F317L mutants has been implicated in the emergence of resistance in patients treated with dasatinib.70,73-77 Four separate studies have shown that the T315I mutant accounted for 8% to 70% of dasatinib-resistant mutations.31,70,73-75 A possible explanation for the wide variation is that the studies with a higher incidence of T315I mutant had a larger proportion of BC-CML and Ph+ ALL patients.

The F317L mutant has intermediate in vitro resistance to dasatinib.13 Although CHR were achieved with dasatinib in imatinib-resistant patients harboring this mutant, MCyR were attained in less than 10%.31 The F317L mutant was also detected in 12% to 42% of patients who developed resistance to dasatinib.31,70,73-75 The median OS of patients with the F317L was 19 months from the time of detection and this was similar to that of patients with other mutations.76 The survival was dependent on the phase of disease and the two-year OS was 75% in CP-CML, 50% in AP-CML, and 20% in BC-CML patients.76

The V299L mutant was detected in 12% to 25% of dasatinib-resistant patients.31,73,74 This is a novel mutation that had rarely or never been seen in imatinib-resistant patients.74,77 The V299L mutant retains in vitro sensitivity to imatinib and nilotinib and clinical responses have been observed in patients treated with these compounds.73,77
A possible strategy to suppress the outgrowth of resistant clones is the combination of dasatinib or the other Bcr-Abl TKIs with an inhibitor of T315I. SGX393 is an azaindole which inhibits the growth of cells expressing wild type Bcr-Abl and the T315I mutant, as well as other Bcr-Abl mutants at varying concentrations.\textsuperscript{78} SGX393 also reduced CrkL phosphorylation in primary hematopoietic cells from patients harboring the T315I mutant and inhibited growth of T315I-driven tumors in mice.\textsuperscript{78} In addition, the combination of dasatinib and SGX393 completely inhibited the growth of mutant clones at most dose combinations except at intermediate concentrations of dasatinib and SGX393.\textsuperscript{78}

**Dasatinib cellular influx and efflux**

Multidrug resistance (MDR) due to cross-resistance of mammalian cells to a number of anticancer agents following exposure to one such drug is a well described mechanism of resistance in cancer therapy. This is mediated by an increased expression at the cell surface of the \textit{ABCB1} gene product, P-glycoprotein, an energy dependent efflux pump, which reduces intracellular drug concentrations and leads to ineffective levels of the drug reaching its target.\textsuperscript{79} Imatinib is a substrate of \textit{ABCB1}, and the intracellular levels of imatinib were shown to be significantly lower in \textit{ABCB1}-expressing cells.\textsuperscript{65,80–82} However, \textit{ABCB1} overexpression has not been reported in patients who are resistant to imatinib. Two other drug transporters, \textit{ABCG2} and \textit{hOCT1}, have been implicated as possible mechanisms for promoting imatinib resistance. Imatinib has been reported to be a substrate and/or an inhibitor for the \textit{ABCG2} drug efflux pump which is overexpressed in many human tumors and also found to be functionally expressed in CML stem cells.\textsuperscript{64,83,84} The drug transporter \textit{hOCT1} mediates the active transport of imatinib into cells, and inhibition of \textit{hOCT1} decreases the intracellular concentration of imatinib, which may predict for a less favorable molecular response.\textsuperscript{65,66}

The cellular influx of dasatinib, on the other hand, is not affected by \textit{hOCT1} activity, although its efflux may be mediated by \textit{ABCB1} and \textit{ABCG2}.\textsuperscript{55,86} The intracellular concentration of dasatinib was lower in \textit{ABCB1}-overexpressing cell lines and was increased in the presence of PSC833, a potent \textit{ABCB1} inhibitor.\textsuperscript{85} The \textit{in vitro} concentration of dasatinib required to inhibit phosphorylation of CrkL by 50\% (dasatinib IC\textsubscript{50}) was higher in the \textit{ABCB1}-overexpressing cell lines compared to parental cell lines (100 nM versus 7 nM), and this was reduced to 8 nM with the addition of PSC833.\textsuperscript{88} Similar results were also seen in the \textit{ABCG2}-overexpressing cell lines, suggesting that high levels of \textit{ABCG2} reduced dasatinib intracellular concentration, leading to an increased dasatinib IC\textsubscript{50}, which can be modulated with \textit{ABCG2} inhibitors.\textsuperscript{85}

The intracellular concentration of dasatinib in primary cells from CP-CML patients was not significantly decreased with the addition of \textit{hOCT1} inhibitors.\textsuperscript{85,86} Dasatinib IC\textsubscript{50} was also not significantly different in \textit{hOCT1}-overexpressing or control cell lines and in cells from patients with high or low \textit{hOCT-1} activity.\textsuperscript{85,86} In addition, there was no correlation between the intracellular concentration of dasatinib and dasatinib IC\textsubscript{50} in newly diagnosed CP-CML patients.\textsuperscript{85}

**Disease persistence**

Small numbers of primitive nondividing stem cells have been identified to be refractory to the pro-apoptotic effect of imatinib and conventional chemotherapeutic agents.\textsuperscript{87} The insensitivity of these ‘quiesscent’ cells also has important implications for the management of CML with regards to minimal residual disease and relapse following imatinib-induced response. Although dasatinib significantly inhibited CrkL phosphorylation and caused a reduction in the total number of CD34+CD38– CML cells compared to imatinib, it did not eliminate the most primitive, quiesscent fraction.\textsuperscript{88} Recently, the farnesyl transferase inhibitor, BMS-214662 was reported to enhance the cytotoxic effect of imatinib or dasatinib in primary CD34+ CML cells and significantly reduce the numbers of undivided primitive quiesscent CML stem cells, either alone or in combination with imatinib or dasatinib.\textsuperscript{89} This effect was selective and normal stem cells were relatively spared. The cytotoxic action was via apoptosis as evidenced by enhanced caspase-3 activity.\textsuperscript{89} BMS-214662 is currently in phase I trials in acute myeloid leukemia and the possibility of clinical trials in CML is being explored.\textsuperscript{89}

**Conclusion**

Dasatinib, through its increased potency and ability to bind Bcr-Abl with less stringent conformational requirements, is clinically effective in the treatment of imatinib-resistant CML, leading to durable hematologic and cytogenetic responses and improved PFS and OS. It is generally well tolerated but, due to its wider spectrum of kinase inhibition, certain toxicities occur more frequently than with other TKIs. Dasatinib resistance, due to Bcr-Abl kinase mutation and potentially overexpression of drug efflux transporters, will represent the next therapeutic challenge in CML. Pre-clinical data suggests that combination treatment may prevent the selection of resistant mutants and eradicate primitive stem cells but this will require clinical validation and will represent the next phase of development.
Disclosure
Dr Charles Chuah has received honoraria from Bristol-Myers Squibb (BMS) and is on the advisory board of BMS and Novartis Pharma. Prof. Junia Melo has no conflict of interest in this work.

References


